Risk of venous thromboembolism with rheumatoid arthritis

Summary

Rheumatoid arthritis is not generally considered to be a risk factor for venous thromboembolism (VTE), although abnormalities of coagulation factors have been found in patients with rheumatoid arthritis. Sparse data in a few patients suggest that patients with rheumatoid arthritis may have higher rates of VTE. The purpose of this investigation was to determine if the incidences of pulmonary embolism (PE) and deep venous thrombosis (DVT) are increased in hospitalized patients with rheumatoid arthritis. The number of patients discharged from non-Federal short-stay hospitals throughout the United States from 1979 through 2005 with a discharge code for rheumatoid arthritis was obtained from the National Hospital Discharge Survey (NHDS). Among hospitalized patients with rheumatoid arthritis who did not have joint surgery, 41,000 of 4,818,000 (0.85%) had PE compared with 3,366,000 of 891,055,000 (0.38%) among patients who did not have rheumatoid arthritis and who did not have operations or joint surgery (relative risk =2.25). Deep venous thrombosis was diagnosed in 79,000 of 4,818,000 (1.64%) patients with rheumatoid arthritis and no joint operation, versus 7,681,000 of 891,055,000 (0.86%) who did not have rheumatoid arthritis or a joint operation (relative risk=1.90). The relative risk of venous thromboembolism (PE and/or DVT) in these patients was 1.99. The data suggest that rheumatoid arthritis is a risk factor for VTE in hospitalized medical patients. A heightened awareness of the risks for VTE and a lower threshold for evaluation of patients for possible DVT or PE would be appropriate in caring for hospitalized patients with rheumatoid arthritis.

Keywords

Pulmonary embolism - deep venous thrombosis - venous thromboembolism - rheumatoid arthritis

• References

• 1 Geerts WH, Bergqvist D, Pineo GF. et al. Preventive of venous thromboembolism. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8^th ed. Chest 2008; 133: S381-S453.
• 2 Seriolo B, Accardo S, Garnero A. et al. Anticardiolipin antibodies, free protein S levels and thrombosis: a survey in a selected population of rheumatoid arthritis patients. Rheumatology 1999; 38: 675-678.
• 3 McEntegart A, Capell HA, Creran D. et al. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology 2001; 40: 640-644.
• 4 Jurado M, Páramo JA, Gutierrez-Pimentel M. et al. Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders. Thromb Haemost 1992; 68: 516-520.
• 5 US Department of Health and Human Services, Public Health Service, National Center for Health Statistics National Hospital Discharge Survey 1979–2005.. Multi-year Public-Use Data File Documentation. Available at http://www.cdc.gov/nchs/about/major/hdasd/nhdsdes.htm. Last accessed 22.07.2008.
• 6 Buchanan RR, Kraag G. Is there a lower incidence of deep venous thrombosis after joint replacement in rheumatoid arthritis?. J Rheumatol 1980; 07: 551-554.
• 7 van Heereveld HA, Laan RF, van den Hoogen FH. et al. Prevention of symptomatic thrombosis with short term (low molecular weight) heparin in patients with rheumatoid arthritis after hip or knee replacement. Ann Rheum Dis 2001; 60: 974-976.
• 8 Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1986; 89 Suppl 26S-35S.
• 9 Piazza G, Seddighzadeh A, Goldhaber SZ. Double trouble for 2,609 hospitalized medical patients who developed deep vein thrombosis: prophylaxis omitted more often and pulmonary embolism more frequent. Chest 2007; 132: 554-561.
• 10 Cohen AT, Tapson VF, Bergmann JF. et al. ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008; 371: 387-394.
• 11 Kahn SR, Panju A, Geerts W. et al. CURVE study investigators. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res 2007; 119: 145-155.
• 12 Doan QV, Chiou CF, Dubois RW. Review of eight pharmacoeconomics studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm 2006; 12: 555-569.
• 13 Infliximab (Remicade) approved for use in rheumatoid arthritis. www.rheumatology.org/publications/hotline/0200infliximab.asp?aud=mem. Last accessed 26.08.2008.
• 14 Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. J Am Med Assoc 2006; 296: E1-E14.
• 15 Ranganathan P. An update on methotrexate pharmacogenetics in rheumatoid arthritis. Pharmacogenomics 2008; 09: 439-451.
• 16 Hoffmeister RT. Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am J Med 1983; 75: 69-73.
• 17 White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 1998; 128: 737-740.
• 18 Kniffin Jr WD, Baron JA, Barrett J. et al. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1994; 154: 861-866.
• 19 Stein PD, Kayali F, Olson RE. et al. Pulmonary thromboembolism in Asian/Pacific Islanders in the United States: Analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census. Am J Med 2004; 116: 435-442.
• 20 Proctor MC, Greenfield LJ. Pulmonary embolism: diagnosis, incidence, and implications. Cardiovasc Surg 1997; 05: 77-81.
• 21 Stein PD, Henry JW. Prevalence of acute pulmonary embolism in a general hospital and at autopsy. Chest 1995; 108: 978-981.
• 22 Stein PD, Patel KC, Kalra NJ. et al. Estimated incidence of acute pulmonary embolism in a community/ teaching general hospital. Chest 2002; 121: 802-805.